Status:
COMPLETED
Defining Remission With Etanercept in AS in Real Life Clinical Practice
Lead Sponsor:
Pfizer
Conditions:
Ankylosing Spondylitis
Eligibility:
All Genders
18+ years
Brief Summary
Determine which remission criterion at Month 6 predicts remission at Month 12 the best.
Detailed Description
The analysis of the primary endpoint will be based on a logistic regression defining the dependent variable as the remission at Month 12 and the 6 independent variables as ASAS partial remission, ASAS...
Eligibility Criteria
Inclusion
- Patients with AS who start treatment with Etanercept according to prevailing reimbursement criteria and dosing in line with SmPC.
- First cohort: Etanercept is the first biological product prescribed
- Second cohort: Etanercept is the second biological product prescribed
- Capable of understanding and willing to provide signed and dated written, voluntary informed consent before any protocol-specific procedures are performed.
- 18 years of age or older at time of consent
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion
- 1\. History of or current psychiatric illness that would interfere with the subject's ability to comply with protocol requirements or to give informed consent.
Key Trial Info
Start Date :
August 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 26 2017
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT02202850
Start Date
August 12 2014
End Date
April 26 2017
Last Update
November 30 2018
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann - Site Horta
Brussels, Bruxelles-capitale, Région de, Belgium, 1020
2
ASZ Aalst
Aalst, Belgium, 9300
3
Algemeen Stedelijk Ziekenhuis
Aalst, Belgium, B-9300
4
Onze Lieve Vrouw Ziekenhuis Aalst
Aalst, Belgium, B-9300